Literature DB >> 2435855

Depression and Parkinson's disease: possible role of serotonergic mechanisms.

V S Kostić, B M Djuricić, N Covicković-Sternić, L Bumbasirević, M Nikolić, B B Mrsulja.   

Abstract

Depression is frequently encountered in Parkinson's disease and was seen to occur in 14 of 26 patients studied. The levels of 5-hydroxyindoleacetic acid (5-HIAA), the main metabolite of serotonin (5-HT), in CSF samples of the patients were significantly lower than in those of controls. However, within the group of patients the levels of 5-HIAA in CSF samples were significantly lower in the depressive subgroup compared with the non-depressive patients. Moreover, no correlation was recorded between motor disability and depression. The results indicate that disturbed 5-HT metabolism may possibly play a role in Parkinson's disease as a predisposing factor in the development of depression.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 2435855     DOI： 10.1007/bf00314109

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


  14 in total

1.  Brain-noradrenaline and 3-methoxy-4-hydroxyphenylglycol in Parkinson's syndrome.

Authors:  P Riederer; W Birkmayer; D Seemann; S Wuketich
Journal:  J Neural Transm       Date:  1977       Impact factor: 3.575

2.  The fluorometric assay of catecholamines and related compounds: improvements and extensions to the hydroxyindole technique.

Authors:  R Laverty; K M Taylor
Journal:  Anal Biochem       Date:  1968-02       Impact factor: 3.365

3.  Psychiatric disturbances in Parkinson's disease.

Authors:  G G Celesia; W M Wanamaker
Journal:  Dis Nerv Syst       Date:  1972-09

4.  Treatment of parkinsonism with levodopa.

Authors:  M D Yahr; R C Duvoisin; M J Schear; R E Barrett; M M Hoehn
Journal:  Arch Neurol       Date:  1969-10

5.  Psychiatric symptoms during l-dopa therapy for Parkinson's disease and their relationship to physical disability.

Authors:  R H Mindham; C D Marsden; J D Parkes
Journal:  Psychol Med       Date:  1976-02       Impact factor: 7.723

6.  "Serotonin depression"--a biochemical subgroup within the affective disorders?

Authors:  M Asberg; P Thorén; L Träskman; L Bertilsson; V Ringberger
Journal:  Science       Date:  1976-02-06       Impact factor: 47.728

7.  Evidence to support early levodopa therapy in Parkinson disease.

Authors:  C H Markham; S G Diamond
Journal:  Neurology       Date:  1981-02       Impact factor: 9.910

8.  Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease.

Authors:  B Scatton; F Javoy-Agid; L Rouquier; B Dubois; Y Agid
Journal:  Brain Res       Date:  1983-09-26       Impact factor: 3.252

9.  Some psychological factors in Parkinsonism.

Authors:  S Horn
Journal:  J Neurol Neurosurg Psychiatry       Date:  1974-01       Impact factor: 10.154

10.  Altered serotonin metabolism in depressed patients with parkinson's disease.

Authors:  R Mayeux; Y Stern; L Cote; J B Williams
Journal:  Neurology       Date:  1984-05       Impact factor: 9.910
View more
  31 in total

Review 1.  Potential mechanisms underlying anxiety and depression in Parkinson's disease: consequences of l-DOPA treatment.

Authors:  Karen L Eskow Jaunarajs; Mariana Angoa-Perez; Donald M Kuhn; Christopher Bishop
Journal:  Neurosci Biobehav Rev       Date:  2010-07-06       Impact factor: 8.989

2.  Loss of thalamic serotonin transporters in early drug-naïve Parkinson's disease patients is associated with tremor: an [(123)I]beta-CIT SPECT study.

Authors:  V Caretti; D Stoffers; A Winogrodzka; I-U Isaias; G Costantino; G Pezzoli; C Ferrarese; A Antonini; E-Ch Wolters; J Booij
Journal:  J Neural Transm (Vienna)       Date:  2008-03-12       Impact factor: 3.575

3.  Monoamines, BDNF, IL-6 and corticosterone in CSF in patients with Parkinson's disease and major depression.

Authors:  Sven Pålhagen; Hongshi Qi; Björn Mårtensson; Jan Wålinder; Ann-Kathrine Granérus; Per Svenningsson
Journal:  J Neurol       Date:  2009-10-21       Impact factor: 4.849

Review 4.  Depression in Parkinson's disease. Pharmacological characteristics and treatment.

Authors:  T Tom; J L Cummings
Journal:  Drugs Aging       Date:  1998-01       Impact factor: 3.923

Review 5.  Chronic MPTP administration regimen in monkeys: a model of dopaminergic and non-dopaminergic cell loss in Parkinson's disease.

Authors:  Gunasingh J Masilamoni; Yoland Smith
Journal:  J Neural Transm (Vienna)       Date:  2017-08-31       Impact factor: 3.575

6.  Major depression in Parkinson's disease and the mood response to intravenous methylphenidate: possible role of the "hedonic" dopamine synapse.

Authors:  R Cantello; M Aguggia; M Gilli; M Delsedime; I Chiardò Cutin; A Riccio; R Mutani
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-06       Impact factor: 10.154

7.  Clinical correlates of depressive symptoms in familial Parkinson's disease.

Authors:  Nathan Pankratz; Karen S Marder; Cheryl A Halter; Alice Rudolph; Cliff W Shults; William C Nichols; Tatiana Foroud
Journal:  Mov Disord       Date:  2008-11-15       Impact factor: 10.338

Review 8.  Dopamine and depression.

Authors:  A S Brown; S Gershon
Journal:  J Neural Transm Gen Sect       Date:  1993

9.  The neuropathological basis for depression in Parkinson's disease.

Authors:  Pasquale G Frisina; Vahram Haroutunian; Leslie S Libow
Journal:  Parkinsonism Relat Disord       Date:  2008-06-20       Impact factor: 4.891

Review 10.  Advances in the molecular characterization of tryptophan hydroxylase.

Authors:  S M Mockus; K E Vrana
Journal:  J Mol Neurosci       Date:  1998-06       Impact factor: 3.444
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.